Biocon Limited

Centro De Inmunologia Molecular

Centro De Immunologia Molecular

Biocon India Limited

Biocon Limited & Centro De Immunologia Molecular

Centro De Inmunolgia Molecular

Mylan Gmbh

Ramakrishnan Melarkode

Pradip Nair

Laxmi Adhikary

Jose Enrique Montero Casimiro

Kedarnath Nanjund Sastry

Shrikumar Suryanarayan

Rolando Perez Rodriguez

Josefa Lombardero Valladares

Monalisa Chatterji

Hema Balasubramanian

Sundaraj David Rajkumar

Anand Khedkar

Ramavana Gururaja

Sanjay Tiwari

Nitin Patil

Rakesh Bhaiyyaram Mendhe

Madhav Kulkarni

Harish Venkatraman Pai

Surekha K Prabhu

Bala S Manian

Madhavan Sridharan

Dinesh Baskar

Ankur Bhatnagar

Saravanan Desan

Usha Bughani

Rasika Venkataraman

Sunaina Prabhu

Kriti Shukla

Abhijit Barve

Madenahally Channabasappa Shivakumar

Prijyajit Sengupta

Nilanjan Sengupta

Harish Iyer

Sambasivam Ganesh

Anuj Goel

Nitesh Dave

Acharya Poornaprajna

Poornaprajna Acharya

Anindya Sircar

Ganesh Samvasivam

Ranjit Ravindran Pillai

Laxmikant Vashishta

Abhishek Kulshrestha

Ravindra Belavinakodige Sadashivarao

Shilpa Govinda Ramaswamy

Ravi Shankar Maurya

Pallavi Hajela

Vishika Hegde

Sharath Kumar Mallapura Rangappa

Ramesh Subramani

Devesh Radhakrishnan

Sundaresh Shankar

Sudheer Chivukula

Pawan Kalani

Ranjith Ramakrishna

Shanmugam Thandava Murthy

Narendra Chirmule

Akundi Venkata Sriram

Lakshmi Prabha Varadarajalu

Pinakee Devi Sharma

Vivek Gopal Nayak

Sudeep Sabde

Anita Rao Udiavar

Senthil Thangamuthu

Madhay Kulkarni

Jose Enrique Casimiro

Sharath Kumar Rangappa

Madenahalli Channabasappa Shivakumar

M C Shivakumar

Deepthy Sathyanathan

The present invention relates to a humanized IgG1 isotype anti-CD6 antibody (T1h) that binds to the Scavenger receptor cysteine-rich (SRCR) domain 1 (D1) of CD6 present on the surface of thymic epithelial cells, monocytes, activated T cells and a variety of other cells types.

Monoclonal antibody and a method thereof

The present invention provides an in vitro method for detecting the presence of neutralizing antibodies against recombinant human insulin (rHI) in human serum. It also provides a kit for an in vitro method of detection of the presence of recombinant human insulin (rHI) neutralizing antibodies.

Method for detecting neutralizing antibodies against recombinant human insulin in human serum

The present invention relates to compositions and methods useful for the treatment of lupus using a humanized IgG1 anti-CD6 monoclonal antibody (T1h) that binds to the SRCR domain 1 (D1) of CD6 without blocking the interaction of CD6 with the CD6 ligand Activated Leukocyte Cell Adhesion Molecule (ALCAM).

Monoclonal antibody and a method of use for the treatment of lupus

The present disclosure relates to methods for treatment and prevention of disease conditions mediated by T-helper 17 (Th17) and/or T-helper 1 (Th1) T lymphocytes (T cells). In particular, the present disclosure relates to use of anti-CD6 antibody for treatment of disease conditions mediated by auto-reactive Th17 and Th1 T lymphocytes. The methods of the present disclosure further have utility in methods for modulating an immune response by suppressing production of the cytokine IL-23R, thereby decreasing inflammation mediated by Th17 cells.

Use of a CD6 binding partner and method based thereon

The present invention relates to a method or process for controlling, inhibiting or reducing protein fucosylation in a eukaryote and/or eukaryotic protein expression system. Said method comprises carrying out the protein expression and/or post-translational modification in the presence of an elevated total concentration of manganese or manganese ions.

Methods for controlling fucosylation levels in proteins

The present invention relates to a method or process for controlling, inhibiting or reducing protein fucosylation in a eukaryote and/or a eukaryotic protein expression system. Said method comprises carrying out the protein expression and/or post-translational modification in the presence of an elevated total concentration of manganese or manganese ions.

The present disclosure relates to a process for detecting and optionally quantifying an analyte in a sample in the presence of a soluble target of the analyte. The soluble target forms a complex with the analyte and thus may interfere in determining the total analyte concentration. The process of the present invention utilizes a unique modified citrate buffer for diluting the sample containing the analyte and the soluble target which in turn helps in dissociating the analyte-soluble target complex, thereby enabling the process of the disclosure to detect and optionally quantify measure the analyte accurately.

Process for detection and optional quantification of an analyte

The invention relates to improvised pharmaceutical compositions permitting ingestion via oral delivery of proteins/peptides or their conjugates, and/or cation-insulin conjugate complexes demonstrating desirable pharmacokinetic profiles and potency in efficacy models of diabetes in dogs and humans. A preferred formulation comprises 0.01%-20% w/w of insulin, insulin compound conjugates and/or cation insulin conjugates, 10%-60% w/w of one or more fatty acid components selected from saturated or unsaturated C4-C12 fatty acids and/or salts of such fatty acids and additionally contains optimal amounts of other pharmaceutically suitable polymer excipients which permit improved solubility, dissolution rate and effective bioavailability of poorly water soluble compositions and consistent in-vivo release profiles upon scalability during manufacture. A further aspect of the invention features the process of preparing the aforesaid formulations.

Orally administrable solid pharmaceutical composition and a process thereof

The present invention relates to a method of producing a biologically active polypeptide having insulinotropic activity, the method comprising steps of: (a) transforming a genetically modified host cell that has protease gene knockout, with a polynucleotide vector encoding the polypeptide; and (b) growing the transformed host cell to produce the biologically active polypeptide; and a method of producing a biologically active polypeptide having an N-terminal recognition site His-Gly with insulinotropic activity, the method comprising steps of: (a) transforming a genetically modifiedthat has protease gene STE13 knockout, with a polynucleotide vector encoding the polypeptide; and (b) growing the transformedto produce the biologically active polypeptide.

Method of producing biologically active polypeptide having insulinotropic activity

Growing community of inventors

Karnataka, India

Ramakrishnan Melarkode